Invasive or conservative strategy for stable coronary disease

George Dangas; Anastasios Roumeliotis; Gennaro Giustino

doi:10.1056/NEJMc2024008

Invasive or conservative strategy for stable coronary disease

George Dangas
, Anastasios Roumeliotis
, Gennaro Giustino

Research output: Contribution to journal › Letter › peer-review

3 Scopus citations

Original language	English
Article number	e66
Journal	New England Journal of Medicine
Volume	383
Issue number	10
DOIs	https://doi.org/10.1056/NEJMc2024008
State	Published - 3 Sep 2020

Access to Document

10.1056/NEJMc2024008

Cite this

@article{a10a3c2365f44f9c98d8ac95ff398b80,

title = "Invasive or conservative strategy for stable coronary disease",

author = "George Dangas and Anastasios Roumeliotis and Gennaro Giustino",

note = "Funding Information: Dr. van {\textquoteright}t Hof reports receiving an unrestricted research grant, paid to his institution, from Abbott. No other potential conflict of interest relevant to this letter was reported. Funding Information: Dr. Dangas reports receiving research grants from Bayer and Daiichi Sankyo and consulting fees from Biosensors International and Philips; and Dr. Giustino, receiving consulting fees for serving on an advisory board for Bristol Myers Squibb-Pfizer. No other potential conflict of interest relevant to this letter was reported.",

year = "2020",

month = sep,

day = "3",

doi = "10.1056/NEJMc2024008",

language = "English",

volume = "383",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "10",

}

TY - JOUR

T1 - Invasive or conservative strategy for stable coronary disease

AU - Dangas, George

AU - Roumeliotis, Anastasios

AU - Giustino, Gennaro

N1 - Funding Information: Dr. van ’t Hof reports receiving an unrestricted research grant, paid to his institution, from Abbott. No other potential conflict of interest relevant to this letter was reported. Funding Information: Dr. Dangas reports receiving research grants from Bayer and Daiichi Sankyo and consulting fees from Biosensors International and Philips; and Dr. Giustino, receiving consulting fees for serving on an advisory board for Bristol Myers Squibb-Pfizer. No other potential conflict of interest relevant to this letter was reported.

PY - 2020/9/3

Y1 - 2020/9/3

UR - https://www.scopus.com/pages/publications/85090261044

U2 - 10.1056/NEJMc2024008

DO - 10.1056/NEJMc2024008

M3 - Letter

C2 - 32877597

AN - SCOPUS:85090261044

SN - 0028-4793

VL - 383

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 10

M1 - e66

ER -